CRP and rheumatoid arthritis: In addition to the number of prior therapies, all of these patients had at least moderate disease activity at the start of the study (as measured by DAS28-CRP), fulfilling at least the first two EULAR criteria for difficult-to-treat (D2T) RA [39].